New Leaf Venture Partners’s CRISPR Therapeutics CRSP Stock Holding History

New Leaf Venture Partners’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-444,708	Closed	-$12.7M	–	21
2018 Q4	$12.7M	Hold	444,708	–	–	3.49%	7
2018 Q3	$19.7M	Hold	444,708	–	–	3.59%	7
2018 Q2	$26.1M	Sell	444,708 -150,934	-25%	-$8.6M	6.31%	4
2018 Q1	$27.2M	Buy	595,642 +87,912	+17%	+$3.63M	14.7%	2
2017 Q4	$11.9M	Sell	507,730 -20,000	-4%	-$380K	5.58%	5
2017 Q3	$9.43M	Hold	527,730	–	–	4.38%	7
2017 Q2	$8.45M	Sell	527,730 -58,745	-10%	-$970K	5.94%	6
2017 Q1	$12.8M	Hold	586,475	–	–	6.54%	6
2016 Q4	$11.9M	Buy	+586,475	New	+$11M	8.51%	5

Other funds holding CRSP

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

New Leaf Venture Partners's CRSP Position: Q1 2019 in Review

New Leaf Venture Partners sold out of CRISPR Therapeutics (CRSP) in Q1 2019, closing a stake of 444,708 shares — an estimated $12.7M sold.

New Leaf Venture Partners first reported a position in CRSP in Q4 2016 and held it in 9 quarters. The position peaked at $27.2M in Q1 2018. 170 funds tracked by Wall St. Rank hold CRSP as of Q1 2019.

New Leaf Venture Partners reported no remaining CRISPR Therapeutics position as of Q1 2019 after selling out during the quarter.
New Leaf Venture Partners sold 444,708 CRISPR Therapeutics shares in Q1 2019, an estimated $12.7M.
New Leaf Venture Partners first reported a position in CRISPR Therapeutics in Q4 2016 and held it in 9 quarters.
New Leaf Venture Partners's CRISPR Therapeutics position peaked at $27.2M in Q1 2018.
170 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2019.

Based on New Leaf Venture Partners's 13F filing for Q1 2019, filed 15 May 2019.